Have any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk for treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that give reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk form treatment complications
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications
Any other diseases, cardiovascular, pulmonary, or metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participants at high risk from treatment complications. Disease-Specific Exclusion Criteria:
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
GENERAL: Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications as determined by the investigator
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
Any other chronic medical condition or psychiatric condition, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator’s opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Patients must not have history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ipilimumab or nivolumab or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.
Patients who have history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would preclude the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any clinical laboratory findings give reasonable suspicion of a disease or condition that contraindicates the use of any study medication or render the subject at high risk from treatment
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications
Any other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of Minnelide, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any medical co-morbidity, physical examination finding, or metabolic dysfunction, or clinical laboratory abnormality that renders the patient unsuitable
Patients must not have history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of MGCD516 or nivolumab or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any known diagnoses, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition (other than mesothelin [positive (+)] cancer diagnosis) that would contraindicate the use of an investigational drug, interfere with tumor measurement or lead to an expected life expectancy of less than 6 months as judged by the investigator
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
Patients who have history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications
Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding, or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of bevacizumab or puts the patient at high risk for treatment-related complications
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an IMP, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding that leads to reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or that may render the subject at high risk for treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may reasonably prevent the participant from participating.
Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or renders the participant at high risk from treatment complications (examples include but are not limited to clinically significant non-healing wound, active bleeding, or ongoing fistula or active tuberculosis infection)
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications, including inadequately controlled diabetes or significant cardiovascular disease
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
History of other diseases, metabolic dysfunction, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other disease, metabolic dysfunction, physical examination finding or clinical lab finding that leads to reasonable suspicion of disease or condition that contraindicates the use of an investigational drug, that may affect interpretation of results, or render the subject at a high risk of treatment complications.
History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that leads to reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications
History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk from treatment complications
Any disease(s), psychiatric condition, metabolic dysfunction, or findings from a physical examination or clinical laboratory test result that would cause reasonable suspicion of a disease or condition, that contraindicates the use of pracinostat and/or AZA, that may increase the risk associated with study participation, that may affect the interpretation of the results, or that would make the patient inappropriate for this study
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any other disease, metabolic dysfunction, physical exam finding, or clinical lab finding that leads to reasonable suspicion of disease that contraindicates the use of an investigational drug that might affect interpretation of results or render subject at high risk for treatment complications.
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
Any disease or condition or laboratory finding giving reasonable suspicion of disease or condition that contraindicates the use of bevacizumab or puts the participant at high risk for treatment-related complications
Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator’s opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participants at high risk from treatment complications
Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or renders the participants at high risk from treatment complications
Any other condition, diseases, metabolic dysfunction, active or uncontrolled infections/inflammation, physical examination finding, mental status or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates participation in the clinical study due to safety concerns, compliance with clinical study procedures or that may affect the interpretation of the results
Any other diseases, metabolic dysfunction, physical examination finding, and/or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or may render the participant at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk for treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
General physical condition compatible with the proposed chemotherapy and surgery
Unresectable disease (e.g. immobile node on physical exam, nodal disease that radiographically involves the carotid arteries, nerves)
Has difficulty climbing a flight of stairs or walking eight blocks due to physical impairment
Patients must be without evidence of visceral or bone involvement with metastatic cancer on physical exam or any diagnostic study; extensive nodal involvement is allowed
Patients who have evidence of infection as determined by history, physical exam or laboratory testing (complete blood count and urinalysis) at baseline will be excluded unless otherwise approved by the PI or PI’s designee
In addition, patients who develop evidence of infection (as determined by history, physical exam or laboratory testing) during the study will be discontinued from the study unless otherwise approved by the PI or PI’s designee
Palpable splenomegaly ?5 cm below the lower costal margin in the midclavicular line as assessed by physical examination
Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or screening investigations
PHYSICAL AND LABORATORY TEST FINDINGS
Abnormal finding on physical exam (study physician discretion)
Any mental or physical condition or disease or past medical history that mitigates against following the protocol
Abnormalities on screening physical exam judged by study physicians or supervising physical therapist to contraindicate participation in exercise program compliance
Mini-mental status exam (MMSE) >= 24
In good physical condition to perform low-intensity daily steps (walking)
Willing to use Fitbit band to monitor physical activities
Already doing moderate to high physical activities in their daily life (rapid screener)
Active tuberculosis based on history, symptoms, physical exam, imaging
The patient must be clinically and radiographically node negative (N0) to participate on this protocol; clinically suspicious regional nodes by imaging or physical exam require biopsy evaluation to exclude disease involvement
Palpable spleen of > 10 cm below the left subcostal margin on physical examination at the screening visit OR
Palpable splenomegaly of 5 to 10 cm below left subcostal margin on physical exam AND active symptoms of MF at the screening visit as demonstrated by presence of 1 symptom score ? 5 or 2 symptom scores ? 3 using the Screening Symptom Form
Clinically =< 3 cm unifocal lesion by imaging or physical examination
Evidence by physical examination or mammography of other suspicious masses, densities, or microcalcifications in either breast, unless biopsied and found to be benign
Measurable disease by physical exam
Clinical stage =< T3a based on digital rectal exam and/or =< T3a based on magnetic resonance imaging (MRI) (if done); N0-Nx; M0-Mx (American Joint Committee on Cancer [AJCC] 7th edition)\r\n* T-stage and N-stage will be determined by physical exam including a digital rectal exam and available imaging studies (computed tomography [CT], and/or MRI of the pelvis); for MRI, extracapsular extension is permitted; to distinguish blood from tumor the ideal study would be to acquire T2, T1 noncontrast and T1 dynamic contrast enhanced sequence, although this is not required\r\n* M-stage determined by physical exam, CT of abdomen and pelvis with contrast, and bone scan
Absence of abnormal lymphadenopathy suggesting metastatic PTC on physical examination and/or imaging studies
Patients who have measurable disease must have had X-rays, scans or physical examinations used for tumor measurement completed within 28 days prior to initial administration of drug
Based on the neurosurgeon’s judgment, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventricles
History and physical including neurological exam, height, weight, cranial skin exam, and Karnofsky performance status >= 70% within 30 days prior to registration
Inability to participate in study activities due to physical or mental limitations
Tumor measures at least 1 centimeter on imaging or physical exam
Inability to participate in study activities due to physical or mental limitations
No evidence of distant metastatic disease as documented by history and physical examination (radiographic staging only to be performed as indicated by symptoms or physical findings)
Nutritional and general physical condition must be considered compatible with the proposed radiation +/- chemotherapy treatment
Evidence of clinically significant neuropathy (> Grade 1) by physical exam.
History of liver decompensation: ascites noted on a physical exam, imaging or other test; variceal bleeding; hepatic encephalopathy
Patients must have fully intact mental status and normal neurologic abilities. Intact mental status is defined by ‘the capacity to identify and recall one's identity and place in time and space. Assessment of mental status and documentation of fully intact mental status by pediatric criteria, will be completed using physical and mental exam by the referring doctor or oncologist
Patients must be without evidence of visceral or bone involvement with metastatic cancer on physical exam or any diagnostic study; extensive nodal involvement is allowed
Patients with radiographic ascites that is apparent on physical exam or requiring medical intervention (medication or procedures) in the 2 months prior to enrollment
Based on the neurosurgeon's judgement, there is no anticipated physical connection between the post-resection tumor cavity and the cerebral ventricles
Physical and Laboratory Test Findings
Physical examination indicates Tanner Stage 1
Clinical evidence of ascites by physical exam
Palpable splenomegaly or hepatomegaly of more than or equal to 5 cm below left or right, respectively, costal margin on physical exam
Appropriate stage for protocol entry, including no clinical evidence for distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination, including breast exam and documentation of weight and Karnofsky performance status of 80-100% at study entry
No stage IV (metastatic) disease, however no specific staging studies are required in the absence of symptoms or physical exam findings that would suggest distant disease.
Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
Stable physical and mental health
Patients must have fully intact mental status and normal neurologic abilities; intact mental status is defined by the capacity to identify and recall one's identity and place in time and space; assessment of mental status and documentation of fully intact mental status will be completed using physical and mental exam by the referring doctor or oncologist
PHASE II: Patients must be without evidence of visceral or bone involvement with metastatic cancer on physical exam or any diagnostic study; extensive nodal involvement is allowed
No stage IV (metastatic) disease, however no specific staging studies are required in the absence of symptoms or physical exam findings that would suggest distant disease.
Tumor diameter =< 2 cm on physical exam & imaging studies
Tumors > 2 cm in diameter on physical exam or imaging studies
Patients must be without visceral or bone involvement with metastatic breast cancer on physical exam or any diagnostic study; patients with extensive nodal involvement classified as stage IV disease, are eligible
Chronic GVHD manifestations that can be followed on physical or laboratory exam\r\n* Skin changes\r\n* Oral mucosa changes\r\n* Hepatic dysfunction\r\n* Diarrhea
The tumor should be approximately at least 1 cm, to account for variability in imaging and imaging occult disease (physical exam, mammography, ultrasound); we recognize that from time to time because of this variation, there might not be enough tissue available for analysis after surgical excision but this will allow the greatest opportunity to capture as many eligible patients as possible
Any physical, social, or psychiatric condition that would prevent effective cooperation or participation in the study
The patient must have a history and physical documented within four weeks of registration and be deemed by a medical oncologist to be ineligible for standard continuous course chemoradiotherapy with cisplatin
Measurable, non-bony disease (at least one lesion on radiographic or physical exam assessment measuring >= 2 cm in longest axis), as demonstrated by imaging or physical exam performed =< 28 days of study entry, provided no anti-tumor therapies or interventions have occurred in that time period
Palpable splenomegaly ? 5 cm on physical examination
Palpable primary breast tumor measuring >= 2.0 cm on physical exam or imaging prior to neoadjuvant chemotherapy
Presence of detectable (by physical exam) third-space fluid collections
Palpable splenomegaly of more than or equal to 5 cm below left costal margin on physical exam
Patients must have laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to surgery as assessed by preoperative anesthesia assessment
Physical and Laboratory Test Findings
Unable to participate in all necessary study activities due to physical or mental limitations
Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or baseline investigations.
History and physical exam, and Karnofsky performance status of >= 70 within 30 days prior to registration
Bedridden, or physical debilitation such that study participation would not be feasible or would create undue hardship
Self-reported sexual dysfunction (Derogatis Interview for Sexual Functioning [DISF]-Male [M]-II score =< 20 in the sexual desire domain), and/or fatigue (Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue [F] score < 30), or physical dysfunction (self-reported difficulty in walking a 1/4 mile or climbing two flights of stairs, and short physical performance battery score [SPPB] between 4 to 9)
Has physical limitations that would prevent participation (e.g. blindness)
Myopathic or rheumatologic disease that impacts physical function
Dementia as assessed by a mini-mental status exam (MMSE) score < 24 on initial screening
Physical handicap that would prevent participation in program
Impairments in physical function, as defined by a score < 9 on the SPPB pre-screen
Patients who have difficulty walking or may not be able to complete the physical therapy measures
Any physical or mental health condition that would interfere with full participation in the study, including individuals who are unable to read consent materials or appear to lack the capacity to consent
Has difficulty climbing a flight of stairs due to physical impairment
Inability to travel to the NIH, for example, due to physical limitations, for the in-person evaluation(s)
Physical limitations (e.g., orthopedic, central nervous system) that contraindicate participation in a low to moderate intensity home-based walking program
A Mini-Mental State Exam Score (MMSE) of at least 26
Children who meet the above criteria, but whose treating oncologist advises against study participation for physical health, mental health (parent or child) or logistical reasons
Patient has physical and mental capabilities to take part in study
Chronic GVHD manifestations that can be followed on physical or laboratory exam; these include but are not necessarily limited to:\r\n* Skin changes \r\n* Oral mucosa changes\r\n* Bronchiolitis obliterans\r\n* Ocular changes
A score of 26 or below on the Mini Mental Status Exam (MMSE) triggers a review by an investigational team before enrolling
Myopathic or rheumatologic disease that impacts physical function
Suspected or confirmed physical closure of salivary gland ducts on either side
Physical exam demonstrating evidence of radiotherapy-related mucositis in the visible oral cavity and/or oropharynx consistent with mucous membrane toxicity greater than 0 using the Acute Radiation Morbidity Scoring Criteria
Absence of tumors:\r\n* Patients must undergo thorough physical examination of the leg undergoing surgery; if physical exam is equivocal for presence of tumors, then a normal magnetic resonance imaging (MRI) of the lower extremity will be required before eligibility is met\r\n* If there is evidence of plexiform neurofibroma or nodular neurofibroma of > 3 cm diameter on the ipsilateral leg, then they are ineligible for the study
Plexiform neurofibroma of any size, or nodular neurofibroma of > 3 cm diameter involving the ipsilateral leg, including the hip\r\n* If presence of plexiform is suspected but not certain on physical exam, MRI of the leg may be indicated to rule this out
Patient cannot comfortably be set up in the prone position (i.e. physical disability)
Unresectable disease (e.g. immobile node on physical exam, nodal disease that radiographically involves the carotid arteries, nerves)
Patients who are not able to use telephone-based interactive voice response software due to physical limitations (e.g., impaired hearing)
Suspected or confirmed physical closure of salivary gland ducts on either side
Individuals with a physical or mental impairment which would preclude their ability\n             to perform the intervention.
Physical deformities that could interfere with accurate acupuncture point location
Individuals unable to complete art therapy activities independently due to physical and/or mental impairment
Mini mental state exam score less than 19
Able to participate occasionally in mildly strenuous physical effort
Physical deformities that could interfere with accurate acupuncture point location
CESM and MRI exam performed within 3 months of one another
Subjects who, at screening, have abnormal vital signs and/or physical exam, including a temperature >= 38.0 C, systolic blood pressure =< 90 or > 180 mmHg, pulse =< 60 or > 130 beats per minute, new rash, signs of infection
Physical limitations that prevent participant from exercising
Documented splenomegaly of at least 5 cm below the costal margin as measured on inspiration by physical exam.
Any physical or mental limitation that would prevent participation in study activities (Including but not limited to grade 4 neuropathy or inability to ambulate)
Stable physical/mental health
Stable physical/mental health
In stable physical/mental health
stable physical/mental health,
Patients presenting to surgery clinic after receipt of NAC at outside hospital with documentation of cT4 or cN2/3 disease on initial outside physical exam and imaging studies
Patients receiving NAC and having a nodal complete clinical response as assessed by physical exam
Clinically detectable disease either by physical examination or radiographic studies
Physical limitation that would limit compliance with the study requirements
Must not have had an injection of a radioisotope 24 hours prior to exam
Physical limitation that would limit compliance with the study requirements
Normal tone on clinical exam
Evidence of distant disease on physical exam or initial imaging
Participant with at least one neck that is clinically N0 as defined by clinical exam (physical exam with CT and/or MRI as the gold standard of the N0 neck); stages T2, T3, or T4. N0–N3, excluding N2c for bilateral disease based on criteria from the American Joint Commission on Cancer
Patients with a grade 1/2 tumors and evidence of deep myometrial invasion or cervical involvement on preoperative imaging or physical exam
Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination
Clinical evidence of T1-4N1-2, T3-4N0 disease; this can be either by imaging studies or by physical exam findings
Medical history, physical exam, and vital signs within 30 days of enrollment
Patients must not have signs of bowel perforation necessitating surgery or “acute” abdomen evidenced by peritonitis on physical exam within 2 days prior to registration
Has not seen a doctor for an annual physical within the last year, not including an annual required physical for work, at baseline
Myopathic or rheumatologic disease that impacts physical function (PCS study)
Unable to provide consent due to a mental, emotional, or physical handicap, that keep them from understanding the consent information
Obvious physical or mental disability that would prevent participant from interacting with a tablet device
Major physical disability which would prevent subject from transferring from a chair to a bed and sitting in an upright position
Patients must have histologically confirmed invasive breast cancer with stage IV disease, either biopsy proven or with unequivocal evidence of metastatic disease by physical examination or radiological study
Patients must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Participants must have histologically confirmed invasive breast cancer, with locally advanced or metastatic disease; patients without pathologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation; for subjects in Cohort C, the tumor must also be hormone receptor positive, defined as demonstrating at least 1% tumor cell nuclei staining positive for either ER or progesterone receptor (PR)
Patients must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation\r\n* Measurable disease: patients must have measurable CNS disease, defined as at least one parenchymal brain lesion that can be accurately measured in at least one dimension with the longest diameter >= 10 mm by local radiology review (measurable non-CNS disease is not required for study participation)\r\n* Patients will be defined as HER2 positive (+) if either the primary tumor and/or the metastasis are HER2-positive, defined as 3+ by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) >= 2.0
Participants must have histologically or cytologically confirmed stage IV invasive breast cancer. Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Pathologically confirmed squamous cell carcinoma of the head and neck with evidence of metastatic disease or locally recurrent disease considered incurable by local therapies; patients without pathologic or cytologic evidence of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Participants must have histologically or cytologically confirmed invasive breast cancer, with metastatic disease; participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Participants must have histologically or cytologically confirmed invasive breast cancer, with either locally advanced or metastatic disease; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Participants must have histologically or cytologically confirmed invasive breast cancer, with metastatic disease; participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Participants must have histologically or cytologically confirmed invasive breast cancer, with unresectable locally advanced or metastatic disease; participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Patients must have histologically or cytologically confirmed invasive breast cancer, with metastatic disease; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis by physical exam or radiologic study
Patients must have histologically or cytologically confirmed stage IV invasive breast cancer; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
There are no minimal organ function requirements for enrollment on this study\r\n* Note: Previous cardiac repair with sufficient cardiac function is not an exclusion criteria
Adequate pulmonary and cardiac function to undergo surgical resection
Abnormal cardiac function defined by a LVEF <50% by ECHO or MUGA
Adequate physical function as measured by all of the following:
Adequate Cardiac Function defined as shortening fraction of >=27% by echocardiogram (while not receiving medications for cardiac function), or ejection fraction of >= 50% by gated radionuclide study (while not receiving medications for cardiac function), the corrected QTc interval by Bazett's formula (QTcB) <450 milliseconds (msec), and must not have a history of myocardial infarction, severe or unstable angina, peripheral vascular disease or familial QTc prolongation.
Adequate pulmonary and cardiac function
Adequate cardiac left ventricular function
Adequate cardiac function as assessed by history and physical examination
Adequate cardiac function as assessed clinically by history and physical examination.
Adequate cardiac function as assessed clinically by history and physical examination.
Hematopoietic function as follows:
Adequate cardiac function as assessed by history and physical examination
Medically significant cardiac event or unstable cardiovascular function defined as:
Reproductive function:
Cardiac function suitable for protocol-required hydration as determined by the investigator and/or cardiologist
Adequate pulmonary and cardiac function: no clinical evidence of cardiopulmonary disease, which, in the opinion of the investigator, precludes enrollment
Adequate cardiac function defined as no history of clinically significant arrhythmia, or history of myocardial infarction (MI) within 3 months prior to study enrollment; cardiac function will be assessed by history and physical examination
Evidence of adequate cardiac function as demonstrated by EKG and/or echocardiography.
Adequate cardiac function (adequate perfusion; no ischemia) on thallium (or technetium [Tc]) stress test
Adequate cardiac function as assessed clinically by history and physical examination
Immunological Function: Adequate immune system function in the opinion of the Investigator with no known immunodeficiency disease.
Normal Cardiac function: as assessed by history and physical exam.
The patient has adequate pulmonary function
Cardiopulmonary function criteria:
Decreased cardiac function with NYHA > Class 2
Subjects must have adequate hematopoietic function as evidenced by:
Adequate blood clotting function
Adequate cardiovascular function
Adequate cardiac function as assessed clinically
Adequate cardiac function as measured by echocardiogram
Adequate cardiac function
Adequate neurologic function
Adequate cardiac function
Abnormal heart function
Adequate cardiac function defined as no clinically significant history of arrhythmia as determined by the principal investigator (PI) and/or the treating physician, history of myocardial infarction (MI) or clinically significant abnormal electrocardiogram (EKG), as determined by the PI and/or the treating physician, within 3 months prior to study enrollment; cardiac function will be assessed by history and physical examination
DONOR: Adequate cardiac function by history and physical examination; those with a history of cardiac problems should undergo a stress evaluation or be evaluated by a cardiologist and deemed eligible to donate
Adequate cardiac function as assessed clinically.
Acceptable cardiac function as indicated by protocol
Cardiac function within normal range
Reproductive Function
Adequate cardiac function
Adequate cardiac function:
Have adequate cardiac function
CARDIOPULMONARY FUNCTION CRITERIA
Abnormal heart function
Normal cardiac function cardiac function by appropriate image testing.
Normal Cardiac function
Adequate cardiac function.
Adequate pulmonary function
Neurological function class of 0-2
Patients who are status post revascularization procedures with satisfactory cardiac function are eligible
Cardiac and pulmonary function that is adequate for ASCT
normal cardiac function
Normal baseline cardiac function based upon pre-operative evaluation at the physician's discretion
At the discretion of the physician or surgeon, normal baseline cardiac function based upon pre-operative evaluation
Subjects who have cardiac or known circulatory impairment, and/or the inability to perspire (poor thermoregulatory function)
Normal baseline cardiac function based upon pre-operative evaluation
Adequate cardiac function (? NYHA Class II) or normal cardiac function with left ventricular ejection fraction (LVEF) ? 50% at screening.
Adequate hematopoietic function within 7 days prior to C1D1
Normal cardiac conduction and function (centrally read)
Patients must have a complete history and physical examination within 28 days prior to registration
Patients must have a complete history and physical examination within 28 days prior to registration
Patients must have a complete physical examination and medical history within 28 days prior to step 2 randomization
Patients must have complete history and physical examination within 28 days prior to registration
Patients must have a complete physical examination and medical history within 28 days prior to registration
Patients must have complete history and physical examination within 28 days prior to registration
History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration
Patients must have a complete history and physical examination within 28 days prior to registration
History/physical examination within 28 days prior to step 2 registration
History/physical examination within 90 days prior to Step 1 registration
Patients must have complete history and physical examination within 28 days prior to registration
History/physical examination, including neurologic examination within 60 days prior to step 2 registration
History/physical examination within 21 days prior to study entry
Patients must have complete history and physical examination within 28 days prior to registration
History/physical examination with digital rectal examination of the prostate and baseline toxicity assessment within 90 days prior to randomization.
Must have a pertinent history/physical examination within 90 days prior to registration
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 28 days prior to registration\r\n* Radiographic imaging of the chest, abdomen and pelvis within 28 days prior to registration documenting disease consistent with FIGO stage III or IV disease\r\n* Further protocol-specific assessments
Participants must have a complete history and physical examination within 45 days of study entry\r\n* Participants must have a digital rectal examination (confirming clinical stage T1c to T2c) of prostate within 180 days of study entry
History/physical examination within 7 days prior to registration
General history and physical examination within 8 weeks prior to registration
Participants must have a complete history and physical examination within 60 days of study entry
General history and physical examination by a radiation oncologist and medical oncologist within 4 weeks prior to enrollment.
History/physical examination within 30 days prior to registration
History/physical examination within 30 days prior to registration
History/physical examination by the treating physician within 24 hours prior to registration
History/physical examination with digital rectal examination of the prostate within 90 days prior to study enrollment
History and physical with neurological examination, height, and weight within 14 days prior to registration
Patients must have a complete history and physical examination within 30 days prior to registration
No evidence of distant metastasis based on a history/physical examination (to include at least digital rectal examination of the prostate and assessment of the abdomen and skeletal system)
Within 30 days of registration: patients must have vital signs, history/physical examination, laboratory studies (complete blood count panel [CBCP] with differential, chemistries including liver function tests, creatinine clearance [CrCl] assessment; pregnancy test if needed within 14 days of registration)
Patient must have a history/physical examination with digital rectal examination of the prostate within 90 days prior to screening
History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration
History/physical examination with digital rectal examination of the prostate within 90 days prior to registration
History and physical with neurological examination, steroid documentation, height, and weight within 14 days of registration
Completion of a comprehensive evaluation, including clinical history and physical examination, to eliminate other causes of their symptoms
History/physical examination within 42 days prior to registration to document cervical tumor size and stage
History/physical examination to include, at a minimum, digital rectal examination of the prostate and examination of the skeletal system and abdomen, and formal comorbidity assessment via the Charlson Comorbidity Index within 60 days prior to registration
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 28 days prior to registration\r\n* Imaging of the chest, abdomen and pelvis within 30 days prior to registration
Patients must have a complete history and physical examination within 30 days prior to registration
History/physical examination within 28 days prior to registration
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 28 days prior to registration\r\n* Imaging of target lesion(s) within 28 days prior to registration\r\n* Completion of pre-study protocol specific assessments as required
History and physical examination including weight, performance status, and body surface area within 8 weeks prior to study registration
Patients must have complete history and physical examination within 28 days prior to registration
Complete history and physical examination noting in detail the exact size and location of any lesions that are detected on examination will be performed within 30 days prior to initiation of chemotherapy
History/physical examination, including documentation of weight, within 2 weeks prior to registration
History and physical examination within 6 weeks of registration
Patients must have a complete history and physical examination within 28 days prior to registration
Patients must have a complete physical examination and medical history within 28 days prior to registration
Patients must have a complete history and physical examination within 28 days prior to registration
Patients must have a complete physical examination and medical history within 28 days prior to registration
Complete history and physical examination including weight and Zubrod status within 31 days of study entry (or within 31 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)
Patients must have a complete physical examination and medical history within 28 days prior to registration
Patients must have complete history and physical examination within 28 days prior to registration
History/physical examination within 30 days prior to registration
History/Physical examination by a Radiation Oncologist and Medical oncologist prior to entering the study.
Patients must have history and physical examination within 28 days prior to registration
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 42 +/- 5 days of planned surgical procedure (18-21 days from day 1);\r\n* Further protocol-specific assessments
History/physical examination within 7 days prior to registration
History/physical examination within 45 days prior to study registration
Patients must have a complete physical examination and medical history within 28 days prior to Step 2 Randomization
Appropriate stage for protocol entry, based upon the following minimum diagnostic workup within 60 days prior to registration:\r\n* History/physical examination including weight, performance data, body surface area
History/physical examination (to include, at a minimum, digital rectal examination of the prostate and examination of the skeletal system and abdomen, and formal comorbidity assessment via the ACE-27 instrument) within 60 days prior to registration; Note: the ACE-27 is posted on the 0815 protocol information page on the NRG Oncology/Radiation Therapy Oncology Group (RTOG) web site
History/physical examination
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 28 days prior to registration
Presence of any clinically significant findings at entry for medical history, laboratory values, or physical examination
Patients must have a complete physical examination and medical history within 28 days prior to registration
History/physical examination, including neurologic examination, within 14 days prior to registration
History/physical examination within 28 days prior to registration
Patients must have a complete physical examination and medical history within 28 days prior to registration
Physical examination, and scans needed for tumor assessment must be performed within 90 days prior to registration
History/physical examination within 60 days prior to registration to document cervical tumor size and stage
History/physical examination with digital rectal examination of the prostate within 8 weeks prior to registration
History/physical examination within 30 days prior to registration
Measurable disease by radiographic or physical examination
Patients must have a history and physical examination obtained within 28 days prior to registration
Measurable tumor by physical or radiographic examination
Unstable brain or leptomeningeal disease based on history and physical examination.
History and physical examination, including neurologic examination, within 2 weeks prior to registration
History and physical with neurological examination, steroid documentation, height, and weight within 14 days of registration
History, physical and performance status of 2 or less within 180 days prior to registration
Patients must have a complete physical examination and medical history within 28 days prior to registration
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) of the brain with contrast within 30 days prior to registration
Patients must have complete physical examination and medical history obtained within 28 days prior to registration
History/physical examination within 14 days prior to registration
History/physical examination within 2 weeks prior to registration
History and physical examination within 28 days prior to Step 2 registration
Have complete history and physical examination documenting no clinical evidence of disease within 8 weeks of registration
History/physical examination within 30 days prior to registration
Pathologically proven diagnosis of cancer any stage, based upon the following minimum diagnostic workup:\r\n* History & physical examination, including documentation of Karnofsky performance status of 70-100% for at least 60 days prior to study entry
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
